Nektar Therapeutics Operating Lease, Liability, Current
Nektar Therapeutics (NKTR) had Operating Lease, Liability, Current of $22.71 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-14
- 2026-06-30: Operating Lease, Liability, Current $22.71M.
- 2026-03-31: Operating Lease, Liability, Current $22.53M.
- 2025-12-31: Operating Lease, Liability, Current $20.50M.
- 2025-09-30: Operating Lease, Liability, Current $22.18M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $22.71M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $22.53M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $20.50M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $22.18M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $22.01M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $21.84M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $19.87M 10-K · filed 2026-03-13 |
| 2024-09-30 | $21.50M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $21.34M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $19.37M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $19.26M 10-K · filed 2025-03-14 |
| 2023-09-30 | $19.09M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $18.93M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $18.77M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $18.67M 10-K · filed 2024-03-05 |
| 2022-09-30 | $18.51M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $20.05M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $19.60M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $17.44M 10-K · filed 2023-02-28 |
| 2021-09-30 | $17.74M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $16.78M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $15.77M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $13.91M 10-K · filed 2022-03-01 |
| 2020-09-30 | $15.35M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $15.14M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $15.61M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $12.52M 10-K · filed 2021-02-26 |
| 2019-09-30 | $9.32M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $3.75M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $1.65M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |